Determination of deflazacort in human plasma by liquid chromatography-mass spectrometry after liquid-liquid extraction and its application in human pharmacokinetics studies

Abstract

**Purpose:** A sensitive liquid chromatography–mass spectrometric (LC/MS) has been developed and validated for the quantification of deflazacort in human plasma after liquid-liquid extraction (LLE). **Materials and Methods:** Best chromatographic resolution was achieved on a reverse-phase Phenomenex C$_18$ column with the mobile phase of acetonitrile–water (30:70) and isocratic elution resulted in a total run time of about 3.5 min. The analyte was detected by using an electrospray positive ionization mass spectrometry in the selected ion monitoring (SIM) mode. Linearity was obtained in the concentration range studied (5–150 ng/ml) ($r = 0.9974$). **Results:** Lower limit of quantification (LLOQ) was found to be 5 ng/ml in 500 µl plasma sample. Average recovery of the analyte was found to range from 86.80 to 88.19% in plasma at the concentrations of 15.0, 60.0 and 120.0 ng/ml. **Conclusions:** The present method was successfully applied in the pharmacokinetic study of deflazacort in human plasma.

Key words: Bioavailability, deflazacort, liquid chromatography–mass spectrometric, liquid-liquid extraction, pharmacokinetics

INTRODUCTION

Deflazacort$^{[1]}$ is chemically 11beta, 21-dihydroxy-2’-methyl-5’ beta-h-pregna-1,4- deino [17,16-d] oxazole-3,20-acetate. Deflazacort is a derivative of glucocorticoid; It is used for its anti-inflammatory properties in conditions responsive to corticosteroid therapy. $\lambda_{\text{max}}$ of deflazacort is 208 nm, which shows its poor ultraviolet (UV) absorption characteristics. Hence determination of deflazacort using HPLC–UV will be a hard task, lacks sensitivity and requires long chromatographic run time in biological fluids. Due to the high polarity index of deflazacort the gas chromatographic (GC) method requires complex and time-consuming derivatization procedures. Limited analytical techniques were available in the assay of deflazacort such as liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS).$^{[5-7]}$ The present liquid chromatography–mass spectrometry method is relatively simple, rapid and highly sensitive in the determination of deflazacort in human plasma after liquid-liquid extraction (LLE) and has been successfully applied in the human pharmacokinetic study.

MATERIALS AND METHODS

**Chemicals and reagents**

Deflazacort (purity: 99.67%) and pantoprazole (internal standard, IS 99.01% purity) were obtained from M/s. Orchid pharmaceuticals (Chennai, India) and Cadila Pharm (Ahmedabad, India). Acetonitrile was of HPLC grade and obtained from E.Merck (Mumbai, India) and other chemicals used were
of analytical grade. Purified water from a Milli-Q-
system (Millipore, Bangalore, India) was used through
analysis.

**Reference and test products**
Reference Product: Defelzacort 6 mg
Test Product: A (Defelzacort 6 mg)

**Human**
Each product was subjected in to 12 volunteer. Human
studies were approved by human ethical committee,
Ooty, India.

**Instrumentation**
A Shimadzu 2010 A LC–MS (including two LC-
10ADvp pumps, an online vacuum deaerator, a
constant temperature automatic sampler, a quadruple
mass spectrometer equipped with an electrospray
ionization interface (ESI) source and LC–MS solution
(Version 2.04) was used for data processing. A
six-port switching valve was used to direct HPLC
elude to a waste container in the first 1.5 min of the
chromatographic run and afterwards to the ionization
source.

**Chromatographic conditions**
Liquid chromatographic separations were achieved
using a Phenomenex 5μ C₁₈ column (100mm×4.6mm).
The column and auto sampler tray temperature were kept constant at 40 and 4 C, respectively. The
mobile phase consisted of a mixture of water (A)
and acetonitrile (B) (70:30) and was delivered at a
flow-rate of 0.3 ml min. The sample injection volume
was 10 μl.

**Mass spectrometric conditions**
Samples were ionized by positive-ion electrospray
ionization mode under the following source conditions:
Gas flow:1.5 1 min; curved desolvation line (CDL)
voltage was fixed as in tuning, CDL temperature:
250 C; and block temperature:200 C. Mass spectra
were obtained at a dwell time of 0.2 and 1 s for SIM
and scan mode accordingly. Analysis was carried out
using selected ion monitoring (SIM) for specific m/z
441.95 for deflazacort and m/z 384.0 for pantoprazole.
Peak areas for all components were automatically
integrated using LC/MS lab solution Version 2.04
(© 2010 A Shimadzu Corp.).

**Preparation of stock and sample solutions**
Stock solution of deflazacort was prepared by
dissolving the accurately weighed reference
compound in water and acetonitrile (1:1) to give a
final concentration of 1 mg ml, stored at 4°C until
it is used. The solution was then serially diluted
with water and mixed with blank human plasma to
achieve standard working solutions at concentration
of 5.0, 10.0, 25.0, 50.0, 75.0, 100.0 and 150.0 ng ml
for deflazacort, respectively. A 2500.0 ng ml internal
standard working solution was prepared by diluting
the 1 mg ml stock solution of internal standard with
Millipore water.

**Sample preparation**
A 0.5 ml aliquot of human plasma sample was mixed
with 0.1 ml of internal standard working solution
(2500.0 ng/ml of pantoprazole) and 1.0 ml of borate
buffer of pH 9.0 were added and mixed. The resulting
solution was vortexed and extracted with ethyl acetate
(3x2 ml). The upper organic layer was separated,
evaporated and the drug was reconstituted using 0.5
ml of the mobile phase and analysed.

**Assay validation**

*Sensitivity and specificity*
The lower limit of quantification was determined as
the minimum concentration that could be accurately
and precisely quantified (lowest data point of the
standard curve). The specificity of the assay for the
analytes versus endogenous substances in the matrix
was assessed comparing the lowest concentration in
the calibration curves with reconstitutions prepared
with drug-free plasma from five different humans.

*Accuracy and precision*
The accuracy and precision (presented as relative
standard deviation, R.S.D.) of the assay were
determined using quality control (QC) samples
at 15.0, 60.0 and 120.0ng/ml. Accuracy (%) was
determined by the percentage ratio of measured
over spiked QC concentration (mean of measured/
spiked×100%). Intra-day precision was determined
by analyzing replicate aliquots of QCs (n = 5 per
each concentration) on the same day. Inter-day
precision was determined by repetitive analysis of
QC samples (each concentration) on five consecutive
days.

*Recovery and ionization*
To investigate the recovery of deflazacort by the LLE
method, plasma samples were spiked with deflazacort
at concentrations of 5, 15.0, 60.0 and 120.0 ng ml. The
resulting peak–area ratios (analyte: Internal standard)
were compared with that of the standards prepared
in mobile phase to provide the recovery values. Ion suppression of ionization was evaluated by comparing the absolute peak areas of control plasma extracted and then spiked with a known amount of drug, to neat standards injected directly in the same reconstitution solvent.

**Stability**
To evaluate sample stability after three freeze–thaw cycles and at room temperature, five replicates of QC samples at each of the low, medium and high concentrations were subjected to three freeze–thaw cycles or were stored at room temperature for 4 h before sample processing, respectively. Five replicates of QC samples at each of the low and high concentrations were processed and stored under autosampler conditions for 24 h. Stability was assessed by comparing the mean concentration of the stored QC samples with the mean concentration of freshly prepared QC samples.

**Application of the assay**
The developed LC/MS assay method was used in the pharmacokinetic study after oral (6.0 mg) administration of deflazacort to human volunteers. Volunteers were fasted for 12 h before dosing and 4 h afterwards, with free access to water. The venous blood samples (6 ml) were withdrawn via an indwelling cannula at predose and at 0.5,1.0,1.5,2.0,2.5,3.0,4.0,6.0,8.0,12.0,18.0 and 24 h following drug administration in each period of the study. The samples were collected in pre-labeled vacutainers containing sodium citrate as the anti-coagulant and centrifuged at 4000 rpm for 10 min at 15ºC and plasma was collected in pre-labeled sample collection tube. A wash out period of 7 days was observed between the two phases of the study. The samples were stored in the deep freezer at -70 ± 5 ºC until analyzed by a validated LC/MS method.

**RESULT AND DISCUSSION**

**Method validation**

**Specificity**
The full scan mass spectra\(^5\) of deflazacort and Pantoprazole (IS) after direct injection in mobile phase are presented in Figure 1. The predominant protonated molecules found for deflazacort were m/z 441.95. The mass spectrometric parameters were optimized to obtain the higher signal for the selected ion 441.95, which also showed less internal interference. While using the isocratic programme, observed retention times were about 3.29 and 1.46 min for deflazacort and pantoprazole, respectively. No additional peaks due to endogenous substances that could have interfered with the detection of the compounds of interest were observed. The LC-MS chromatogram of blank plasma [Figure 2] and plasma spiked with deflazacort chromatograms are presented in Figures 3 and 4.

**Linearity and lower limit of quantification**
The linear regression analysis of deflazacort constructed by plotting the peak–area ratio of deflazacort to the internal standard (y) versus analyte concentration (μg ml) in spiked plasma samples (x). The calibration curves were fluctuated in the range of 5.0–150ng ml. The average regression equation of these curves and their correlation coefficients (r) were calculated it showed good linear relationship between the peak areas and the concentrations. The lower limit of quantitation was 5 ng ml for determination of deflazacort in plasma. The limit has already been sufficient for pharmacokinetic studies of deflazacort.

**Precision**
The intra-day precision (presented as relative standard deviation) is shown in Table 1. The accuracy, defined as (measured concentration/spiked concentration) ×100%, reached from 93.07 to 99.65% through out the

---

**Figure 1:** Mass spectrum of deflazacort and pantoprazole at positive mode scan
four concentrations examined. The inter-day precision was studied over five days.

Recovery and stability
The absolute recoveries of deflazacort at concentrations of 15.0, 60.0 and 120.0 ng ml \( (n = 5) \) were 86.60±5.75, 86.57±8.59 and 88.19±9.15\%, respectively. Stability of deflazacort during sample handling (freeze–thaw and short-term temperature) and the stability of processed samples were evaluated and deflazacort was stable for at least 4 h at room temperature in plasma samples, for 24 h in autosampler conditions and in plasma samples following three freeze–thaw cycles.

Ionization
It was shown that LLE improves the sample clean-up to remove internal substances from plasma and thereby decrease the amount of matrix injected onto the column, thus the ion suppression effect was minimized. The results indicated that there was no significant difference between the signals of analytes extracted from human plasma and the mobile phase, which proves that there were no matrix effects.

Pharmacokinetic study
The assay was conducted to obtain pharmacokinetic data for deflazacort in human plasma after oral administration (6.0 mg) application of the LC/MS method developed here to \textit{in vivo} pharmacokinetic studies in humans. The area under the plasma concentration (AUCs curve) of deflazacort after oral administrations were 2830.15±380.84 and 2854.16±657.50 ng h ml, respectively. The mean \( C_{\text{max}} \) value was 66.66±4.10 and 69.60±3.46 ng/mL corresponding mean \( t_{\text{max}} \) value was 1.88±0.43 and 1.75±0.26 h. The mean plasma elimination half-life was 2.40±0.31 and 2.58±0.28 h. for test and...
reference respectively [Figure 5, Table 2]. Other pharmacokinetic parameters in this study are shown in Table 2. The present method could be applied to pharmacokinetic studies after a lower dose administration of deflazacort (6 mg).

**CONCLUSIONS**

LLE of deflazacort from plasma was found to be more precise than the solid phase extraction. The current method guarantees a high precision, accuracy, recovery and a relatively short analysis time and will be a useful tool in the pharmacokinetic study of deflazacort in humans.

**REFERENCES**

1. Maryadele J. The Merck Index. In: O’Neil, editor. 13th ed. Whitehouse Station, NJ, USA: The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals; 2001. p. 501.
2. Möllmann H, Hochhaus G, Rohatagi S, Barth J, Derendroff H. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in human plasma. Int J Pharm. 2006;320(1-2):97-103.
comparison to methylprednisolone and prednisolone. Pharm Res 1995;12:1096-100.
3. Reynolds DL, Burmaster SD, Eichmeier LS. Quantitative determination of 21-hydroxy-deflazacort in human plasma using gradient semi-microbore liquid chromatography. Biomed Chromatogr 1994;8:230-5.
4. Rao N, Eller M, Brougham T, Weir S. The effect of food on the relative bioavailability of deflazacort. Eur J Drug Metab Pharmacokinet 1996;21:241-5.
5. Latta K, Krieg RJ, Hisano S, Veldhuis JD, Chan JC. Effect of the synthetic glucocorticoid, deflazacort, on body growth, pulsatile secretion of GH and thymolysis in the rat. Eur J Endocrinol 1999;140:441-6.
6. Hirata H, Kasama T, Sawai Y, Fike RR. Simultaneous determination of deflazacort metabolites II and III, cortisol, cortisone, prednisolone and prednisone in human serum by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996;21:241-5.
7. Santos-montes A, Gonzalo-lumbreras R, Gasco-lopez A, Lzquierdo-omillos R, J Chromatogr B Biomed Appl 1994;657:248-53.
8. FDA Guidance for Industry. Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) 2001.

How to cite this article: Selvadurai M, Meyyanathan SN. Determination of deflazacort in human plasma by liquid chromatography-mass spectrometry after liquid-liquid extraction and its application in human pharmacokinetics studies. Pharm Methods 2011;2:106-11.
Source of Support: Nil, Conflict of Interest: None declared.

**Staying in touch with the journal**

1) **Table of Contents (TOC) email alert**
   Receive an email alert containing the TOC when a new complete issue of the journal is made available online. To register for TOC alerts go to www.phmethods.org/signup.asp.

2) **RSS feeds**
   Really Simple Syndication (RSS) helps you to get alerts on new publication right on your desktop without going to the journal’s website. You need a software (e.g. RSSReader, Feed Demon, FeedReader, My Yahoo!, NewsGator and NewsCrawler) to get advantage of this tool. RSS feeds can also be read through FireFox or Microsoft Outlook 2007. Once any of these small (and mostly free) software is installed, add www.phmethods.org/rssfeed.asp as one of the feeds.